Skip to content

Efficacy of Atomoxetine in the treatment of ADHD symptoms in autistic children

Efficacy of Atomoxetine in the treatment of ADHD symptoms in autistic children

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20240925063160N1
Enrollment
30
Registered
2024-11-03
Start date
2024-11-21
Completion date
Unknown
Last updated
2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention-Deficit/ Hyperactivity Disorder (ADHD). Attention-deficit hyperactivity disorders

Interventions

Intervention group: Children receiving atomoxetine at a daily dose of 10 mg for 12 weeks.

Sponsors

Oroumia University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
4 Years to 12 Years

Inclusion criteria

Inclusion criteria: No history of atomoxetine use, informed consent from parents to participate in the study, diagnosis of ADHD according to the assessment of a pediatric neurologist

Exclusion criteria

Exclusion criteria: The presence of other neurological and psychiatric disorders alongside the diagnoses made by pediatric neurologists

Design outcomes

Primary

MeasureTime frame
ADHD rating scale. Timepoint: before intervention and 4, 8 , 12 months after intervention. Method of measurement: ADHD Rating Scale Questionnaire.

Secondary

MeasureTime frame
Revised Connors Parent Scale score. Timepoint: before intervention and 4, 8 , 12 months after intervention. Method of measurement: Revised Connors Parent Scale Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Ahad Ghazavi

Oroumia University of Medical Sciences

Ghazavi.a@umsu.ac.ir+98 44 3223 7080

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026